SOLNATIDE partners
APEPTICO Forschung und Entwicklung GmbH (APEPTICO) is a private Austrian biotechnology company with headquarters in Vienna. APEPTICO develops peptide-based products targeting chronic and life-threatening diseases with peptide molecules having synthetically produced protein structures to avoid risks associated with commonly used gene and cell technologies.
One of these developments is the therapeutic peptide solnatide, which is being investigated in the H2020-funded SOLNATIDE project.
What we do for the SOLNATIDE project
APEPTICO is the Scientific Coordinator of the SOLNATIDE project and the main clinical study sponsor.
Moreover, we are the work package leaders of WP5 (Solnatide IMP Formulation & Manufacture) and mainly involved in WP1 (Ethical Requirements).
CEO of APEPTICO, Bernhard Fischer
“We are very proud to work together with the consortium of the SOLNATIDE project for the development of an innovative medicine for the treatment of severe CODID-19 patients.”
BCN
www.bcnpeptides.com
LMU
www.lmu-klinikum.de
OPIS
www.opisresearch.com
BCN Peptides (BCN) is a privately owned Spanish company located near Barcelona whose main focus is manufacturing bioactive peptides for pharmaceutical and veterinary applications. The BCN scientific team provides excellent expertise on synthetic peptide chemistry and analytics, especially on long sequences and cyclic peptides for manufacturing generic as well as custom peptides.
Certainly, BCN has an excellent GMP compliance track record with all major institutions (e.g. FDA, EDQM, PMPDA, etc.) for its state-of-the-art facility.
What we do for the SOLNATIDE project
BCN is leading WP4 (Solnatide API Manufacture & Characterisation) and will manufacture the solnatide active pharmaceutical ingredient for the project.
BCN Sales Manager Jordi Piró on SOLNATIDE
“We are committed to improve the health of the people, so we are very proud and excited about the opportunity of collaborating with APEPTICO and the SOLNATIDE consortium to bring medicine to the market that saves lives, especially severely ill COVID-19 patients.”
APEPTICO Forschung und Entwicklung GmbH (APEPTICO) is a private Austrian biotechnology company with headquarters in Vienna. APEPTICO develops peptide-based products targeting chronic and life-threatening diseases with peptide molecules having synthetically produced protein structures to avoid risks associated with commonly used gene and cell technologies.
One of these developments is the therapeutic peptide solnatide, which is being investigated in the H2020-funded SOLNATIDE project.
What we do for the SOLNATIDE project
APEPTICO is the Scientific Coordinator of the SOLNATIDE project and the main clinical study sponsor.
Moreover, we are the work package leaders of WP5 (Solnatide IMP Formulation & Manufacture) and mainly involved in WP1 (Ethical Requirements).
CEO of APEPTICO, Bernhard Fischer
“We are very proud to work together with the consortium of the SOLNATIDE project for the development of an innovative medicine for the treatment of severe CODID-19 patients.”